BioCryst Pharmaceuticals (BCRX) reported Q4 adjusted loss Monday of $0.13 per diluted share, narrower from a loss of $0.28 a year earlier.
Four analysts polled by FactSet expected loss of $0.06.
Revenue for the quarter ended Dec. 31 was $131.5 million, up from $93.4 million a year earlier. Analysts surveyed by FactSet expected $130.1 million.
BioCryst Pharmaceuticals now expects full year 2025 total revenue of $560 million and $575 million, compared with the previous forecast of $540 million to $560 million. Analysts surveyed by FactSet expect $548.9 million.
Shares were down 3% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.